(Q34666327)

3 August 2017

title

The role of 3-O-methyldopa in the side effects of L-dopa (English)

1 reference

3 August 2017

Eun-Sook Y Lee

1

1 reference

3 August 2017

Hongtao Chen

series ordinal

2

1 reference

3 August 2017

Jennifer King

series ordinal

3

1 reference

3 August 2017

Clivel Charlton

series ordinal

4

1 reference

3 August 2017

publication date

24 August 2007

1 reference

3 August 2017

published in

Neurochemical Research

1 reference

3 August 2017

volume

33

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

401-411

1 reference

Effects of 3-OM-dopa on monoamine metabolism in rat brain

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11064-007-9442-6

The metabolism of L-3-0-methyldopa, aprecursor of dopa in man

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11064-007-9442-6

Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11064-007-9442-6

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease

21 January 2018

1 reference

12 December 2020

Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.

1 reference

12 December 2020

Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease

1 reference

12 December 2020

Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection

1 reference

12 December 2020

L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase

1 reference

12 December 2020

Effects of homocysteine on the dopaminergic system and behavior in rodents

1 reference

12 December 2020

Differential cytotoxicities of N-methyl-beta-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease

1 reference

12 December 2020

Levodopa toxicity and apoptosis

1 reference

12 December 2020

3-OMD and homocysteine plasma levels in parkinsonian patients

1 reference

12 December 2020

Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells

1 reference

12 December 2020

Does O-methyl-dopa play a role in levodopa-induced dyskinesias?

1 reference

12 December 2020

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

12 December 2020

Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation

1 reference

12 December 2020

Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.

1 reference

12 December 2020

Catecholamines and indoleamines in the central nervous system of a urodele amphibian: a microdissection study with emphasis on the distribution of epinephrine

1 reference

12 December 2020

The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease

1 reference

12 December 2020

Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum

1 reference

12 December 2020

Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease

1 reference

12 December 2020

3-O-methyldopa and motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid.

1 reference

12 December 2020

Catecholamines potentiate amyloid beta-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis

1 reference

12 December 2020

3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease

1 reference

12 December 2020

The toxicity of 6-hydroxydopamine on PC12 and P19 cells

1 reference

12 December 2020

L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation.

1 reference

12 December 2020

Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease

1 reference

12 December 2020

Storage and release of acetylcholine by a clonal cell line

1 reference

12 December 2020

Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data

1 reference

12 December 2020

Continuous monitoring of mitochondrial membrane potential in hepatocyte cell suspensions.

1 reference

12 December 2020

Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor

1 reference

12 December 2020

Aggravation of l-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells

1 reference

12 December 2020

Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats

1 reference

12 December 2020

Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line

1 reference

12 December 2020

3-O-methyldopa blocks dopa metabolism in rat corpus striatum.

1 reference

12 December 2020

1 reference

12 December 2020

3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse

1 reference

12 December 2020

Pharmacokinetics of L-dopa in patients with Parkinson's disease

1 reference

12 December 2020

Catechol-O-methyltransferase activity: a determinant of levodopa response.

1 reference

12 December 2020

Release of [3H]norepinephrine from a clonal line of pheochromocytoma cells (PC12) by nicotinic cholinergic stimulation

1 reference

12 December 2020

Differential effect of catecholamines and MPP(+) on membrane permeability in brain mitochondria and cell viability in PC12 cells

1 reference

12 December 2020

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

1 reference

12 December 2020

Problems with long-term levodopa therapy for Parkinson's disease

1 reference

12 December 2020

Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease.

1 reference

12 December 2020

The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase

1 reference

12 December 2020

Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

1 reference

12 December 2020

Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity.

1 reference

12 December 2020

Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions

1 reference

12 December 2020

10.1007/S11064-007-9442-6

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1038610738

0 references

Fatcat ID

release_ymynfjm335bstjn3o2ep666pm4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ymynfjm335bstjn3o2ep666pm4

24 November 2022

mapped directly with Wikidata item

1 reference